Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

British Journal of Urology

Volumn 80, Issue 5, 1997, Pages 762-765

  Herr, H W ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Bladder tumour; Long term outcome; Progression; T1

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0031400317     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00431.x     Document Type: Article

References (15)

1. Schapers RFM, Pauwels RPE, Wijnen JTM et al. A simplified grading method of transitional cell carcinoma of the urinary bladder: reproducibility, clinical significance and comparison with prognostic parameters. Br J Urol 1994; 73: 625-31
2. Herr HW, Jakse G, Sheinfeld S. The T1 bladder tumor. Sem Urol 1990; 8: 254.
3. Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450.
4. Herr HW, Schwalb DM, Zhang Z-F et al. Intravesical BCG therapy prevents tumor progression and death from superficial bladder cancer: ten-year followup of a prospective randomized trial. J Clin Oncol 1995; 13: 1404.
5. Cookson MS, Herr HW, Zhang Z-F, Soloway S, Fair WR. The treated natural history of high risk superficial bladder cancer: fifteen year outcome. J Urol 1997; 158: 62-8.
6. Eure GR, Cundiff MR, Schellhammer PF. BCG therapy for high risk stage T1 superficial bladder cancer. J Urol 1992; 147: 376.
7. Cookson MS. Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical BCG therapy. J Urol 1992; 148: 797.
8. Pansadoro V, Emiliozzi P, Defidio L et al. BCG in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long term results. J Urol 1995; 154: 2054.
9. Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996; 155: 1907.
10. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose Pasteur BCG regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996; 156: 1602.
11. Sarkis AS, Dalbagni G. Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease expression. J Natl Cancer Inst 1993; 85: 53.
12. Holmang S, Hedelin H, Anderstrom C. Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823.
13. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 1987; 60: 2766.
14. Lacombe L, Dalbagni G, Zhang Z-F, Cordon-Cardo C, Herr HW, Reuter VE. Overexpression of p53 protein in high-risk population of patients with superficial bladder cancer before and after BCG therapy: correlation to clinical outcome. J Clin Oncol 1996; 14: 2646.
15. Herr HW. Progression of T1 bladder tumors after intravesical BCG. J Urol 1991; 145: 40.